The US public health insurance plan - a bridge too far?
This article was originally published in Scrip
US healthcare reform has edged a little closer after the Senate voted to go ahead and debate its own consolidated reform bill. But it is looking increasingly likely that one of the central proposals – the controversial government-run public health insurance scheme – may have to be jettisoned, or at least heavily diluted, if the reform is to pass Congress.
You may also be interested in...
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.